GT Biopharma, Inc.
DB:OXIA 株式レポート
GT Biopharma マネジメント GT Biopharmaの CEO はMichael Breenで、 Mar2022年に任命され、 の在任期間は 2.17年です。 の年間総報酬は$ 1.89Mで、 26%給与と74%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の2.07%を直接所有しており、その価値は€ 80.35K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3.4年です。
主要情報 CEO給与比率 26.0% CEO在任期間 2.2yrs CEOの所有権 2.1% 経営陣の平均在職期間 2.3yrs 取締役会の平均在任期間 3.4yrs
経営陣の近況
GT Biopharma, Inc. Announces CFO Changes Jun 10 GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024 May 01
High number of new and inexperienced directors Jul 26
すべての更新を表示
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia Jun 27
GT Biopharma, Inc. Announces CFO Changes Jun 10 GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million. May 22
GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024 May 01
GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Feb 02
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia Dec 04 GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting Nov 07
Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance Aug 23
New major risk - Revenue and earnings growth Aug 08
High number of new and inexperienced directors Jul 26
CEO報酬分析 GT Biopharma の収益と比較して、Michael Breen の報酬はどのように変化したか? 日付 総報酬 給与 会社業績 Dec 31 2023 n/a n/a -US$8m
Sep 30 2023 n/a n/a -US$10m
Jun 30 2023 n/a n/a -US$15m
Mar 31 2023 n/a n/a -US$16m
Dec 31 2022 US$2m US$493k -US$21m
Sep 30 2022 n/a n/a -US$33m
Jun 30 2022 n/a n/a -US$32m
Mar 31 2022 n/a n/a -US$34m
Dec 31 2021 US$3m US$63k -US$58m
報酬と市場: Michaelの 総報酬 ($USD 1.89M ) は、 German市場 ($USD 480.14K ) の同規模の企業の平均を上回っています。
報酬と収益: Michaelの報酬は、過去 1 年間の会社の業績と一致しています。
CEO(最高経営責任者 Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as an Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and se ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Interim CEO & Executive Chairman 2.2yrs US$1.89m 2.07% € 80.3k CFO & Secretary 2.3yrs US$993.38k 0.85% € 32.8k Consulting Chief Scientific Officer 4.8yrs データなし データなし
もっと見る
経験豊富な経営陣: OXIAの経営陣は 経験豊富 であると考えられます ( 2.3年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Interim CEO & Executive Chairman 3.3yrs US$1.89m 2.07% € 80.3k Consulting Chief Scientific Officer 6.7yrs データなし データなし Independent Director less than a year データなし 0% € 0 Independent Director 3.3yrs US$1.35m 0% € 0 Independent Vice Chairman 3.5yrs US$548.71k 0.85% € 33.1k Scientific Advisor no data データなし データなし Chairman of Science Advisory Board 3.6yrs データなし データなし Member of Scientific & Medical Advisory Board 3.6yrs データなし データなし Member of Scientific Advisory Board 2.8yrs データなし データなし
もっと見る
経験豊富なボード: OXIAの 取締役会 は 経験豊富 であると考えられます ( 3.4年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}